Apellis Pharmaceuticals Reports First Quarter 2019 Business Update and Financial Results
Resumed Dosing in Phase 3 Geographic Atrophy Program Announced Innovative Collaboration & Financing with SFJ Pharmaceuticals® Cash Position of $288.2 Million at Quarter-End WALTHAM Mass. and CRESTWOOD, Ky., May 08, 2019 (GLOBE NEWSWIRE) -- Apellis …